Zoledronate after denosumab treatment in people with osteoporosis
Tests zoledronate after stopping denosumab in adults with osteoporosis.
Key facts
- Who runs it
- Aarhus University Hospital
- Where
- Aalborg and Aarhus N, DenmarkSee the 2 sites
- Trial code
- Registry title
- Treatment with zoledronate subsequent to denosumab in osteoporosis 2
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 1 person, planned
- Started
- 11 May 2023
- Expected to end
- 1 Jan 2029
- Type of study
- Interventional
- Record updated
- 1 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for postmenopausal women who have taken denosumab for osteoporosis for at least two years and had their last injection less than five months ago.
- Age
- 40 years or older
- Sex
- Women only
- Disease stage
- Osteoporosis; postmenopausal for at least two years; at least 2 lumbar vertebrae that can be checked by a DXA bone scan
- Earlier treatment
- Must have had denosumab for at least two years, with the last injection less than five months ago. Long earlier use of some other bone drugs, or recent hormone replacement therapy, is not allowed.
Main reasons for not taking part
- Diabetes
- Low-energy vertebral fracture within the last ten years, or 3 or more at any time
- Low-energy hip fracture within the last 12 months
- Ongoing treatment with systemic glucocorticoids
- eGFR of 35 mL/min or less, or a contraindication for zoledronate
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Postmenopausal women (postmenopausal for at least two years)
- Age ≥ 40 years
- Treatment for at least two years with denosumab
- Last denosumab injection less than five months ago
- At least 2 lumbar vertebrae that can be evaluated by DXA
Who cannot take part
- Treatment with other bisphosphonates (risedronate, ibandronate) for more than three years prior to denosumab treatment within the last five years
- Ongoing treatment with systemic glucocorticoids
- Hormone replacement therapy
- Zoledronate treatment for more than three years prior to denosumab treatment within the last ten years
- Alendronate treatment for more than three years prior to denosumab treatment within the last five years or for more than five years within the last the years
- Diabetes Mellitus
- Metabolic bone disease (for example osteogenesis imperfecta, Paget's disease of bone)
- Active cancer within the last 5 years with the exception of basal cell skin cancer
- Estimated glomerular filtration rate (eGFR) ≤ 35 mL/min
- Low-energy vertebral fracture within the last ten years
- Contraindications for zoledronate according to the SPC
- Unable to read and understand Danish
- Immobility
- Multiple low-energy vertebral fractures (>= 3) at any time
- Low-energy hip fracture within the last 12 months
- BMD T-score < -2.0 (lumbar spine, total hip or femoral neck)
Where in Denmark
- Aalborg University HospitalAalborg, DenmarkTaking people
- Aarhus University HospitalAarhus N, DenmarkTaking people
About the trial
What the trial wants to find out
The aims of ZOLARMAB2 are fourfold. First, we want to investigate if multiple infusions of zoledronate can prevent the rebound activation of bone turnover and the subsequent bone loss in patients previously treated with denosumab and if there is difference between infusing zoledronate at fixed time-points after the last injection of denosumab or when bone turnover is increased. Second, we want to investigate if bone loss will resume after controlling the rebound activation of bone turnover during the first year after denosumab discontinuation and if this can be prevented by yearly infusions of zoledronate. Third, we want to investigate the underlying pathophysiological mechanisms by investigating biochemical markers, oste-oclast and osteoblast activation signals in the bone and bone marrow, and the pool of preosteoclasts/mature osteoclasts before and after treatment with zoledronate. Fourth, we want to investigate the effect of denosumab discontinuation on muscle mass and muscle strength and on insulin sensitivity.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Treatment with zoledronate subsequent to denosumab in osteoporosis 2
- Plain-language title
- Zoledronate after denosumab treatment in people with osteoporosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 1 July 2026